What is Ocrevus (ocrelizumab) for?
Buy Ocrevus (ocrelizumab). Ocrevus (ocrelizumab) is a treatment for people with certain types of multiple sclerosis (MS). It helps those with relapsing or primary progressive MS. It’s the first treatment approved for primary progressive MS.
Relapsing MS has episodes of worsening followed by recovery. Primary progressive MS gets worse from the start, without early relapses or remissions.
How does Ocrevus (ocrelizumab) work?
MS is a chronic disease that affects the central nervous system. It disrupts communication between the brain and other parts of the body.
The immune system causes damage to neurons in patients with MS.
Ocrelizumab works by binding to CD20 on some antibodies. This leads to their death. It’s thought to prevent these antibodies from harming neurons.
Where has Ocrevus (ocrelizumab) been approved?
Ocrevus (ocrelizumab) has been approved for MS in several places:
- Food and Drug Administration (FDA), USA, March 28, 2017
- European Medical Agency (EMA), European Union, January 8, 2018
- Therapeutic Goods Administration (TGA), Australia, July 13, 2017
- Health Canada, September 21, 2017
- Medsafe, New Zealand, December 21, 2017
This medicine might also be approved in other regions. If you have questions, contact our support team.
How is Ocrevus (ocrelizumab) taken?
The standard dosage is:
- Starting dose of 300 mg intravenous infusion (drip), followed two weeks later by a second 300 mg intravenous infusion
- Subsequent doses of 600 mg intravenous infusion every 6 months.
Patients should be monitored closely during and for at least one hour after infusion as injection reactions may be possible.
For more details on dosage and administration, see the official prescribing information. Note: Please consult with your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Ocrevus (ocrelizumab)?
Common Adverse Reactions
Relapsing MS
The most common side effects include:
- upper respiratory tract infections
- infusion reactions.
Primary progressive MS
The most common side effects include:
- upper respiratory tract infections
- infusion reactions
- skin infections
- lower respiratory tract infections.
Serious adverse reactions
The serious side effects include:
- serious infusion reactions requiring hospitalisation
- infections: administration should be delayed in patients with an active infection until the infection is resolved.
- an increased risk of malignancy, including breast cancer, may exist.
Use in a specific population
Ocrevus (ocrelizumab) can harm a fetus. It’s best to avoid pregnancy unless the benefits to the mother are greater than the risks to the baby. It’s not known if Ocrevus is passed through milk to babies. Therefore, it’s advised to stop breastfeeding while taking Ocrevus.
People with weakened immune systems should not start Ocrevus until their health improves.
For a full list of side effects and reactions, see the official prescribing information.
Remember, Occrevus and Ocravis are just misspellings of Ocrevus. They are not different drugs.